Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
Home > Understanding Breast Cancer > Breast Cancer Research > Table 30a: Breast cancer screening with mammography for women 40–49

  


Table 30a: Breast cancer screening with mammography for women 40–49

This summary table contains detailed information about research studies. Summary tables offer an informative look at the science behind many breast cancer guidelines and recommendations. However, they should be viewed with some caution. In order to read and interpret research tables successfully, it is important to understand some key concepts. Learn how to read a research table.

Introduction: For women 40 to 49, mammography screening saves lives, but the benefits are less than for older women.  

The U.S. Preventive Services Task Force meta-analysis of eight randomized controlled trials found that mammography modestly reduced the risk of breast cancer mortality (death) in women 40 to 49 [1]. An American College of Physicians review of 117 studies found that while mammography reduced breast cancer mortality in women 40 to 49, the risk of false positive results was high [2].

Recommendations for mammography screening

Weighing the benefits and risks, the U.S. Preventive Services Task Force no longer recommends routine mammography for all women 40 to 49 [3]. Instead, the Task Force, as well as the American College of Physicians, encourages women 40 to 49 to make informed decisions with their health care providers about when to start mammography screening [3-4].  

Many health organizations, including the American Cancer Society, feel the modest survival benefit of mammography in women 40 to 49 outweighs the risk of false positive results. They recommend routine screening mammograms for women at average risk beginning at age 40.   

Learn more about mammography in women 40 to 49

Learn about the debate over mammography for women of any age.  

Study selection criteria: Large randomized controlled trials and meta-analyses.

Table note: Relative risk above 1 indicates increased risk. Relative risk below 1 indicates decreased risk. 

Study 

Study Population
(number of participants) 

Follow-up 
(years) 

Age at Screening 

Relative Risk of Breast Cancer Mortality (Death) in Women Who Got Screening Mammography Versus Women Who Did Not
 RR (95% CI) 

Randomized controlled trials 

Age Trial (United Kingdom) [5]

161,196

11

age 39-48

0.83
(0.66-1.04)

Canadian National Breast Cancer Screening Study [6]

50,643

25

age 40-49

1.09 
(0.80-1.49)

HIP-study [1]

27,626

18

age 40-49

0.78
(0.56-1.08)

Gothenburg Breast Screening Trial [7]

26,034

14

age 39-49

0.70
(0.46-1.06)

Malmo [1]

25,966

13

age 43-49

0.73
(0.51-1.04)

Stockholm [1]

22,371

14

age 40-49

1.47
(0.77-2.78)

Ostergotland [1]

20,805

17

age 40-49

1.05
(0.64-1.73)

Kopparberg [1]

14,651

13

age 40-49

0.72
(0.38-1.37)

Edinburgh [8]

11,371

14

age 40-49

0.78
(0.46-1.32)

Meta-analyses 

Kerlikowske et al. [9]

13 studies

7-12

age 40-49

0.92
(0.75-1.13)

U.S. Preventive Services Task Force [1]

8 studies

 

age 39-49

0.85
(0.75-0.96)

Cochrane Collaboration [10]

8 studies

13

age <50

0.84
(0.73-0.96)*

 *The combined relative risk for the three studies with good methodology was 0.87 (0.73-1.03). 
 

References  

  1. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L for the U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 151(10):727-37, W237-42, 2009.
  2. Armstrong K, Moye E, Williams S, Berlin JA, Reynolds EE. Screening mammography in women 40 to 49 years of age: a systematic review for the American College of Physicians. Ann Intern Med. 146(7):516-26, 2007.
  3. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 151(10):716-726, 2009.
  4. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening mammography for women 40 to 49 years of age: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 146(7):511-5, 2007.
  5. Moss SM, Cuckle H, Evans A, et al. for the Trial Management Group. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 368(9552):2053-60, 2006.
  6. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence of the Canadian National Breast Screening Study: randomized screening trial. BMJ. 348:g366, 2014. 
  7. Bjurstam N, Björneld L, Warwick J, et al. The Gothenburg Breast Screening Trial. Cancer. 97(10):2387-96, 2003.
  8. Alexander FE, Anderson TJ, Brown HK, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. Lancet. 353(9168):1903-8, 1999.
  9. Kerlikowske K, Grady D, Rubin SM, et al: Efficacy of screening mammography: A meta-analysis. JAMA 273:149-154, 1995.
  10. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 6:CD001877, 2013.

Updated 05/28/14